Biogen price target raised to $400 from $300 at Jefferies. Jefferies analyst Michael Yee raised his price target for Biogen to $400 following the positive Phase II Alzheimer’s data for BAN-2401. After Friday’s rally, the question is whether there is significant incoming moneyflow above and beyond peers as well and what’s risk/reward into the presentation of BAN-2401 data now, Yee tells investors in a research note. The analyst keeps a Hold rating on Biogen shares after analyzing the bull/bear setup for 2018.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.